Pharmacogenetic biomarkers: Cytochrome P450 3A5

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1312-1317

  MacPhee, Iain A M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ciclosporin; Cytochrome P450 3A5; Immunosuppression; Sirolimus; Tacrolimus; Transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; SOTRASTAURIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDC1 GENE; ACUTE GRAFT REJECTION; AGE DISTRIBUTION; AREA UNDER THE CURVE; CYTOCHROME P450 3A5 GENE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG TREATMENT FAILURE; FIRST PASS EFFECT; GENE; GENE INTERACTION; GENETIC VARIABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; NEPHROTOXICITY; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UREMIA;

ALLELES; BIOMARKERS, PHARMACOLOGICAL; CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TACROLIMUS; UREMIA;

EID: 84862766799     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.013     Document Type: Review

References (70)

1. Halloran P.F. Immunosuppressive drugs for kidney transplantation. NewEngl J Med. 2004, 351:2715-2729.
2. Clase C.M., Mahalati K., Kiberd B.A., et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002, 2:789-795.
3. Undre N.A., van Hoof J., Christiaans M., et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999, 31:296-298.
4. Le Meur Y., Djebli N., Szelag J.C., et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006, 80:51-60.
5. Hesselink D.A., van Schaik R.H., van Agteren M., et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008, 18:339-348.
6. Finta C., Zaphiropoulos P.G. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000, 260:13-23.
7. Dai Y., Iwanaga K., Lin Y.S., et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004, 68:1889-1902.
8. Bader A., Hansen T., Kirchner G., Allmeling C., Haverich A., Borlak J.T. Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 2000, 129:331-342.
9. Lampen A., Zhang Y., Hackbarth I., Benet L.Z., Sewing K.F., Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998, 285:1104-1112.
10. Picard N., Rouguieg-Malki K., Kamar N., Rostaing L., Marquet P. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 2011, 91:652-656.
11. Picard N., Djebli N., Sauvage F.L., Marquet P. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 2007, 35:350-355.
12. Thummel K.E., Shen D.D., Podoll T.D., et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994, 271:557-566.
13. Lamba V., Panetta J.C., Strom S., Schuetz E.G. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 2010, 332:1088-1099.
14. Ware N., Macphee I.A. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther 2010, 12:270-283.
15. Garcia-Martin E., Martinez C., Pizarro R.M., et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002, 71:196-204.
16. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
17. MacPhee I.A.M., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002, 74:1486-1489.
18. Fredericks S., Moreton M., Macphee I.A., et al. Genotyping cytochrome P450 3A5 using the Light Cycler. Ann Clin Biochem 2005, 42:376-381.
19. Macphee I.A., Holt D.W. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 2008, 85:163-165.
20. Givens R.C., Lin Y.S., Dowling A.L., et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003, 95:1297-1300.
21. Thompson E.E., Kuttab-Boulos H., Witonsky D., Yang L., Roe B.A., Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004, 75:1059-1069.
22. Hustert E., Haberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11:773-779.
23. Mancinelli L.M., Frassetto L., Floren L.C., et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001, 69:24-31.
24. Thervet E., Loriot M.A., Barbier S., et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010, 87:721-726.
25. Macphee I.A., Fredericks S., Mohamed M., et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005, 79:499-502.
26. Kuypers D.R., de Jonge H., Naesens M., Lerut E., Verbeke K., Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007, 82:711-725.
27. Thorn M., Finnstrom N., Lundgren S., Rane A., Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005, 60:54-60.
28. Berggren S., Gall C., Wollnitz N., et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007, 4:252-257.
29. Goto M., Masuda S., Kiuchi T., et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004, 14:471-478.
30. Uesugi M., Masuda S., Katsura T., Oike F., Takada Y., Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006, 16:119-127.
31. Wehland M., Bauer S., Brakemeier S., et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011, 21:179-184.
32. Benkali K., Rostaing L., Premaud A., et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010, 49:683-692.
33. Ferraresso M., Tirelli A., Ghio L., et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 2007, 11:296-300.
34. Zhao W., Elie V., Roussey G., et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 2009, 86:609-618.
35. Anglicheau D., Le Corre D., Lechaton S., et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005, 5:595-603.
36. Miao L.Y., Huang C.R., Hou J.Q., Qian M.Y. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2007, 29:1-5.
37. Renders L., Frisman M., Ufer M., et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007, 81:228-234.
38. Mourad M., Mourad G., Wallemacq P., et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005, 80:977-984.
39. Kniepeiss D., Renner W., Trummer O., et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant 2011, 25:146-150.
40. Kreutz R., Zurcher H., Kain S., Martus P., Offermann G., Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004, 14:665-671.
41. Fredericks S., Jorga A., MacPhee I.A.M., et al. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 2007, 21:252-257.
42. Bouamar R., Hesselink D.A., van Schaik R.H., et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit 2011, 33:178-184.
43. Kreutz R., Bolbrinker J., van der Sman-de Beer, et al. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J 2008, 8:416-422.
44. Higgins R.M., Morlidge C., Magee P., McDiarmaid-Gordon A., Lam F.T., Kashi H. Conversion between cyclosporin and tacrolimus - 30-fold dose prediction. Nephrol Dial Transplant 1999, 14:1609.
45. Miura M., Satoh S., Inoue K., et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008, 73:1052-1059.
46. Kovarik J.M., Huang H.L., Slade A., Sfikas N., Chandler P.A. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. Br J Clin Pharmacol 2009, 68:381-385.
47. Roberts P.J., Rollins K.D., Kashuba A.D., et al. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos 2008, 36:1465-1469.
48. Chandel N., Aggarwal P.K., Minz M., Sakhuja V., Kohli K.K., Jha V. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics 2009, 19:458-463.
49. Kuypers D.R., de Jonge H., Naesens M., Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008, 18:861-868.
50. Michaud J., Dube P., Naud J., et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005, 144:1067-1077.
51. Nolin T.D., Appiah K., Kendrick S.A., Le P., McMonagle E., Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006, 17:2363-2367.
52. Sun H., Frassetto L.A., Huang Y., Benet L.Z. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther 2010, 87:465-472.
53. Nolin T.D., Frye R.F., Le P., et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 2009, 20:2269-2276.
54. Okabe H., Hashimoto Y., Inui K.I. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. J Pharm Pharmacol 2000, 52:1467-1472.
55. Kuypers D.R., de Jonge H., Naesens M., Vanrenterghem Y. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010, 32:2012-2023.
56. Kirwan C.J., Lee T., Holt D.W., Grounds R.M., Macphee I.A., Philips B.J. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 2009, 35:1271-1275.
57. Thorn M., Lundgren S., Herlenius G., Ericzon B.G., Loof L., Rane A. Gene expression of cytochromes P450 in liver transplants over time. Eur J Clin Pharmacol 2004, 60:413-420.
58. Moreton M., Fredericks S., McKeown D.A., et al. CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the Abbott immunoassay. Clin Chem 2005, 51:2214-2215.
59. Cummins C.L., Jacobsen W., Benet L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002, 300:1036-1045.
60. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002, 54:1295-1310.
61. Quteineh L., Verstuyft C., Furlan V., et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008, 103:546-552.
62. Chen J.S., Li L.S., Cheng D.R., et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc 2009, 41:1557-1561.
63. Singh R., Srivastava A., Kapoor R., Sharma K., Mittal D. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:169-177.
64. Macphee I.A., Fredericks S., Tai T., et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004, 4:914-919.
65. Hesselink D.A., Bouamar R., van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010, 32:387-393.
66. Joy M.S., Hogan S.L., Thompson B.D., Finn W.F., Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 2007, 22:1963-1968.
67. de Denus S., Zakrzewski M., Barhdadi A., et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J Heart Lung Transplant 2011, 30:326-331.
68. Fukudo M., Yano I., Yoshimura A., et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008, 18:413-423.
69. Ng F.L., Holt D.W., Chang R.W., Macphee I.A. Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrol Dial Transplant 2010, 25:628-634.
70. Passey C., Birnbaum A.K., Brundage R.C., Oetting W.S., Israni A.K., Jacobson P.A. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011, Epub.